ライフサイエンスコーパス: CMV

1 CMV colitis was diagnosed as having positive inclusion b

2 CMV D+/R- serostatus, lung transplant, and treatment pha

3 CMV DNA load in BAL can be used to differentiate CMV pne

4 CMV genomes were detected predominantly in lung and also

5 CMV infection in kidney transplant recipients (KTRs) has

6 CMV reactivation is a major complication after allogenei

7 CMV shedding rate and viral load were higher in children

8 CMV tet(low) and tet(high) CTLs had an identical effecto

9 CMV, herpes simplex virus type 1, and human herpesvirus

10 CMV-specific CD8+ (CMV-Tc), CD4+ (CMV-Th) T cell activit

11 CMV-specific T cells directed to CMV-IE1 and CMV-pp65 we

12 CMV-specific T cells were maintained in distinct distrib

13 CMV-T cell activity, anti-CMV IgG, and NK cell-mediated

14 CMV-Tc and/or Th became (-) in 50% to 70% of these sero

15 ramer binding (CMV tet(high) CTLs) in 53/115 CMV IgG(+) patients stem cell transplanted from CMV IgG(

16 al therapy was assessed in 282 patients (147 CMV disease and 135 asymptomatic viremia).

17 0 days (November 10, 2016) that included 160 CMV-seropositive adults with either sepsis or trauma and

18 s DNA results were highly reproducible for 3 CMV virus stocks and WHO IS (P > .80), tested by three s

19 All 30 CMV sero (+) patients were (+) for CMV-Tc and/or Th pred

20 hus, although most people eventually acquire CMV infection, it usually requires numerous exposures.

21 blood) collected from 21 women who acquired CMV.

22 Among CMV-seropositive adults with critical illness due to sep

23 ed by enzyme-linked immunosorbent assay, and CMV DNA by polymerase chain reaction.

24 An assay combining DNase I digestion and CMV quantitative polymerase chain reaction (DNase-CMV-qP

25 , 5.4-164.2) more likely to transmit HIV and CMV to their infants, respectively.

26 CMV-specific T cells directed to CMV-IE1 and CMV-pp65 were measured by interferon-gamma Elispot assay

27 Sex and CMV independently impacted on multiple B-cell and T-cell

28 Importantly, the effects of sex and CMV were in part explained by age and infection with oth

29 to compare the proportion of CMV viremia and CMV retinitis in patients transplanted between January 2

30 Anti-CMV IgG was measured by enzyme-linked immunosorbent assa

31 CMV-T cell activity, anti-CMV IgG, and NK cell-mediated antibody-dependent cell cy

32 not result in prolonged suppression of anti-CMV immunity or increased risk for CMV infection.

33 py, contributing to the repopulation of anti-CMV immunity.

34 Because CMV already impacts on T-cell memory at a young age, we

35 level of 500 IU/mL to differentiate between CMV pneumonia and pulmonary shedding, using current CMV

36 tified CMV-associated TCRbeta molecules bind CMV in vitro, and, moreover, we used this approach to ac

37 MV tet(low) CTLs) and high tetramer binding (CMV tet(high) CTLs) in 53/115 CMV IgG(+) patients stem c

38 the first time, to our knowledge, that both CMV tet(low) and tet(high) CTLs are functional effector

39 CMV-specific CD8+ (CMV-Tc), CD4+ (CMV-Th) T cell activity, and natural killer (NK) cell nu

40 CMV-specific CD8+ (CMV-Tc), CD4+ (CMV-Th) T cell activity, and natural kill

41 operties, and clinical impact of coappearing CMV tet(low) and tet(high) CTLs after allogeneic SCT.

42 t bias, and competing risks, only concurrent CMV and EBV reactivations remained independently associa

43 Congenital CMV infection (cCMV) is the most common congenital infec

44 s the first study to suggest that congenital CMV infection is a risk factor for childhood ALL and is

45 ression of B7-H4 on HIV MDSC, and controlled CMV-specific T cell activity by limiting CMVpp65-IFNgamm

46 PET is effective in controlling CMV in children receiving LT, with lower costs and lower

47 umonia and pulmonary shedding, using current CMV pneumonia prevalence figures.

48 es and predictive models identified a cutoff CMV DNA level of 500 IU/mL to differentiate between CMV

49 Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were the most commonly

50 Cytomegalovirus (CMV) entry into fibroblasts differs from entry into epit

51 Cytomegalovirus (CMV) IgG antibodies have been associated with inflammagi

52 Cytomegalovirus (CMV) infection and disease are important causes of morbi

53 Cytomegalovirus (CMV) infection sometimes causes large expansions of CMV-

54 Cytomegalovirus (CMV) persists in most humans, requires T cell immunity t

55 s viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that re

56 pstein-Barr virus (EBV) and cytomegalovirus (CMV), and compared to bulk memory CD8 T cells.

57 in patients with concurrent cytomegalovirus (CMV) infection and inflammatory bowel disease (IBD).

58 Detectable cytomegalovirus (CMV)-specific T cells in CMV-seronegative kidney transpl

59 lthough initial therapy for cytomegalovirus (CMV) is usually successful, a significant subset of pati

60 anciclovir-resistant (ganR) cytomegalovirus (CMV) is an emerging and important problem in solid organ

61 human herpesvirus 6 (HHV6), cytomegalovirus (CMV), and BK virus screened weekly.

62 Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal

63 A encoding 3 immunodominant cytomegalovirus (CMV) antigens, which stimulates a host antiviral respons

64 e administration.IMPORTANCE Cytomegalovirus (CMV) is a significant cause of birth defects among newbo

65 es exclusively, detected in cytomegalovirus (CMV)- and Epstein-Barr virus (EBV)-responsive CD4+ T cel

66 of 666 subjects with known cytomegalovirus (CMV) serostatus by immunosequencing.

67 The observed cytomegalovirus (CMV) viremia rate for patients at risk was low (15%), as

68 The kinetics of cytomegalovirus (CMV) DNA in infected asymptomatic hosts are largely unkn

69 The role of cytomegalovirus (CMV) reactivation in mediating adverse clinical outcomes

70 quantitative PCR assays of cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus (BKV), adenovir

71 trate that the frequency of cytomegalovirus (CMV)-pp65-specific T-cell responses in peripheral blood

72 n group) revealed prevalent cytomegalovirus (CMV) infection at diagnosis in childhood ALL, demonstrat

73 Quantitative cytomegalovirus (CMV) DNA-specific polymerase chain reaction (PCR) analys

74 posed to superantigen or to cytomegalovirus (CMV) antigen using matched T cells and MCs from CMV-sero

75 Whether cytomegalovirus (CMV) DNA exists in plasma as virion-associated or free D

76 Infection with cytomegalovirus (CMV) can elicit a CD8(+) T cell response restricted by t

77 Persistent infections with cytomegalovirus (CMV) differentially affect the host immune phenotype in

78 udied viremia episodes with cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV

79 ella-zoster virus [VZV] and cytomegalovirus [CMV]).

80 an absence of circulating antibodies despite CMV sensitization.

81 Twenty-four women (9.2%) had detectable CMV viruria by qualitative PCR.

82 One sero (-) patient developed CMV-T cell responses post-CMV viremia.

83 Four patients developed CMV viremia with clearance by 1.2 months, which correlat

84 f 75 patients with immune recovery developed CMV retinitis in the first 6 months after initiating cAR

85 onths after HSCT, participants who developed CMV disease (n = 8) compared with CMV reactivation (n =

86 classification framework that could diagnose CMV status from the resulting catalog of TCRbeta sequenc

87 y colitis patients are suggested to diagnose CMV colitis.

88 While multiple different CMV proteins are recognized, most publications on age-re

89 DNA load in BAL can be used to differentiate CMV pneumonia from pulmonary shedding.

90 uantitative polymerase chain reaction (DNase-CMV-qPCR) was developed to differentiate free naked DNA

91 and all 10 fresh samples tested using DNase-CMV-qPCR.

92 Patients with dual CMV-CTLs had more CMV tet(high) than tet(low) CTLs.

93 During CMV-CTL monitoring using mutated HLA/CMV tetramers selec

94 ive study of 94 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 1

95 Participants experiencing CMV reactivation compared with patients without CMV reac

96 Experimental CMV-based vaccine vectors expressing a single MHC class

97 rospective birth cohort of 30 highly exposed CMV-uninfected infants.

98 Persistent shedding was more common for CMV and EBV when compared to other HHVs.

99 n of IFN-alpha-stimulated genes critical for CMV immunity.

100 Two associated factors for CMV colitis in hospitalized IBD patients were that they

101 sible impact of viremia and risk factors for CMV infection in pediatric LT recipients managed with ga

102 zation (WHO) international standard (IS) for CMV DNA.

103 Although no differences were observed for CMV replication, KTRs with CMV-specific T cells presente

104 December 2013; 32 (32%) tested positive for CMV viremia.

105 n of anti-CMV immunity or increased risk for CMV infection.

106 to be implemented in risk stratification for CMV replication.

107 All 30 CMV sero (+) patients were (+) for CMV-Tc and/or Th predesensitization, while 3 sero (-) pa

108 One hundred three frozen and 10 fresh CMV DNA-positive plasma samples from solid-organ transpl

109 ) antigen using matched T cells and MCs from CMV-seropositive or CMV-seronegative donors, and for ant

110 IgG(+) patients stem cell transplanted from CMV IgG(+) donors.

111 identifying participants at risk of further CMV reactivation.

112 GanR-CMV is associated with longer prior antiviral duration a

113 GanR-CMV was associated with higher mortality (11% vs 1%, P =

114 GanR-CMV was associated with increased prior exposure to ganc

115 recipients with genotypically confirmed ganR-CMV (n = 37) and ganS-CMV infection (n = 109), matched b

116 ge, 90-284 days]) prior to diagnosis of ganR-CMV.

117 f prior drug exposure to guide rational ganR-CMV testing in SOT recipients.

118 /17) of lung transplant recipients with ganR-CMV had received <6 weeks of prior ganciclovir (current

119 on of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk factors and outcomes attributable

120 pically confirmed ganR-CMV (n = 37) and ganS-CMV infection (n = 109), matched by donor/recipient CMV

121 tributable morbidity and mortality than ganS-CMV.

122 e type II (pol II) promoters such as generic CMV and muscle/heart-specific MHCK7.

123 rwent allogeneic HSCT; 13 patients (46%) had CMV viremia, not a statistically significant increase (P

124 Three children had CMV disease; no CMV-related death or graft loss was reco

125 ed the association of 4 human herpesviruses (CMV, herpes simplex virus type 1, human herpesvirus type

126 tively; P = .14), but HEU infants had higher CMV loads (P = .005) and >2-fold higher C-reactive prote

127 HIV/CMV co-infected persons despite prolonged viral suppress

128 During CMV-CTL monitoring using mutated HLA/CMV tetramers selectively detecting high-avidity T cells

129 CD4(+) T cells specific for human CMV (HCMV) are elevated in HIV(+) HCMV(+) subjects.

130 a better understanding of how natural human CMV infection is acquired.

131 ts with a fibroblast-adapted mutant of human CMV (HCMV).

132 The secondary assay identified CMV DNA in 41.5% of asthmatics and 13.3% of control subj

133 also confirmed that three of the identified CMV-associated TCRbeta molecules bind CMV in vitro, and,

134 le cytomegalovirus (CMV)-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) hav

135 ocesses, 27 antibodies targeting epitopes in CMV virion glycoprotein complexes, including glycoprotei

136 ll CD4(+) TH1 proliferation response only in CMV-seropositive donors.

137 We set out to define the role of UL31 in CMV replication.

138 Expansion of HIV-infected CMV/EBV-specific CD4 + T cells may contribute to mainten

139 No antibodies inhibited CMV spread in fibroblasts, including those with potent n

140 ess responses that are capable of inhibiting CMV infection.

141 Isolated CMV tet(low) and tet(high) CTLs were equally sensitive t

142 Chimerism analysis of isolated CMV tet(low) and tet(high) CTLs revealed their exclusive

143 In LNs, CMV-specific T cells exhibited quiescent phenotypes inde

144 appropriate in settings of very high or low CMV pneumonia prevalence.

145 observed coappearance of CMV-CTLs with low (CMV tet(low) CTLs) and high tetramer binding (CMV tet(hi

146 n (HSCT) could assist clinicians in managing CMV-related complications.

147 ive group compared to age and gender matched CMV negative IBD patients (81.8% vs. 51.5%).

148 Maternal CMV viruria was not associated with mean CD4 cell counts

149 ct of calibration to international units/ml (CMV and EBV) on variability was also determined.

150 Our data suggest that monitoring CMV-specific T cell kinetics from pretransplantation to

151 Patients with dual CMV-CTLs had more CMV tet(high) than tet(low) CTLs.

152 ity epitope KCSRNRQYL, and show that a mouse CMV (MCMV) vector provides complete immune control of re

153 The CC chemokine MCK-2 encoded by mouse CMV (MCMV) has an atypical structure consisting of a cla

154 echanistic framework to explain why multiple CMV exposures are typically required before infection is

155 altered neurodevelopment that follows murine CMV infection of the developing brain and that a subset

156 hat support infection, as well as for murine CMV.

157 ction, and during a persistent/latent murine CMV infection.

158 okines in the blood and the brains of murine CMV-infected mice.

159 ion and lytic infection and restricts murine CMV replication in vivo.

160 Here, we used the murine CMV (MCMV) model of infection to determine that IFITM3 l

161 8(+) T cells in the same tumors using murine CMV, a herpesvirus that causes a persistent/latent infec

162 al (Staphylococcus aureus) and viral (murine CMV) infection in vivo.

163 of neural progenitor cells or in vivo murine CMV infection of the mouse brain.

164 n mice that were infected or not with murine CMV (MCMV), a herpesvirus that infects the salivary glan

165 Three children had CMV disease; no CMV-related death or graft loss was recorded.

166 However, no CMV DNA threshold exists in bronchoalveolar lavage (BAL)

167 ization, while 3 sero (-) patients showed no CMV-T cell activity.

168 QR, 0-1.6 log10 IU/mL] for patients with non-CMV pneumonia, 0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] fo

169 onia and 139 controls (100 patients with non-CMV pneumonia, 18 with idiopathic pneumonia syndrome [IP

170 029), and HHV6 (HR, 0.991; P = .012) but not CMV (P = .31) and BK virus (P = .27).

171 In all plasma samples, 98.8%-100% of CMV DNA was free DNA; this was the only form in 93 of 10

172 correlated with an increase or appearance of CMV-T cells, even in the sero (-) patient.

173 Assessment of CMV viremia was restricted to symptomatic cases in the r

174 asthma to establish potential association of CMV DNAemia with asthma and asthma characteristics.

175 benefit of adoptive T-cell therapy (ATCT) of CMV phosphoprotein 65 (pp65)-specific T cells.

176 his study found no change in the capacity of CMV pp65-specific T cells to gain multiple effector func

177 No cases of CMV retinitis were identified.

178 Our recent cluster of CMV retinitis in pediatric allogeneic HSCT patients may

179 avidity T cells, we observed coappearance of CMV-CTLs with low (CMV tet(low) CTLs) and high tetramer

180 C(+) NK cells are involved in the control of CMV in KTRs.

181 outcomes in clinical trials, definitions of CMV infection and disease were developed and most recent

182 may be inversely related with the degree of CMV control.

183 mes, direct and putative indirect effects of CMV, possible impact of viremia and risk factors for CMV

184 an transplant patients with first episode of CMV disease or asymptomatic viremia (>/=1000 IU/mL) requ

185 of relapse in SOTRs following an episode of CMV disease.

186 ts who completed treatment for an episode of CMV infection/disease were included.

187 The first episode of CMV viremia requiring antiviral therapy was assessed in

188 ents after treatment of the first episode of CMV viremia/disease.

189 fection sometimes causes large expansions of CMV-specific T cells, particularly in older people.

190 However, the extent of CMV-mediated regulation of nucleolar biology is not well

191 ssed the prevalence and clinical features of CMV colitis in hospitalized IBD patients.

192 Thus, although the incidence of CMV infection is high during infancy, our data provide a

193 Secondary outcomes were incidence of CMV reactivation in plasma, mechanical ventilation days,

194 patients may suggest a rise in incidence of CMV retinitis.

195 Further investigation of CMV as an etiologic agent for ALL is warranted.

196 plications for elucidating the mechanisms of CMV entry, spread, and antibody evasion and may assist i

197 B affected the infectivity of AMV but not of CMV, correlating with the ability of atALKBH9B to intera

198 We aimed to assess the presence of CMV DNA in the blood of adult and elderly patients with

199 Presence of CMV, EBV, and herpes simplex virus (HSV) were independen

200 th respect to CMV serostatus and presence of CMV-specific T cells.

201 d infants had a similarly high prevalence of CMV (81.4% vs 74.0%, respectively; P = .14), but HEU inf

202 t test was used to compare the proportion of CMV viremia and CMV retinitis in patients transplanted b

203 month period and compare this to the rate of CMV viremia and retinitis in the 4 years prior.

204 A simple test to identify recovery of CMV-specific T-cell immunity following hematopoietic ste

205 urpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infe

206 posttransplantation were at greatest risk of CMV replication.

207 etermine the clinical efficacy and safety of CMV suppression in this setting.

208 1 restored IFN-alpha-mediated suppression of CMV.

209 th quality attributes comparable to those of CMV hyperimmune globulin.

210 strate that use of SP following treatment of CMV disease did not confer long-term protection against

211 roach might have skewed our understanding of CMV-specific immunity at older ages.

212 Positive predictive value of CMV PCR in saliva was 59%; false positive results were a

213 The diagnostic value of CMV-specific T cells, however, needs to be implemented i

214 new-onset CMV retinitis and of worsening of CMV retinitis (either increasing border activity or reti

215 of the plant, while not having any effect on CMV infection.

216 ells to >/=100 cells/muL; rates of new-onset CMV retinitis and of worsening of CMV retinitis (either

217 ith negative pretransplant HBc, HCV, EBV, or CMV serology.

218 After infection of primary cells with HSV or CMV, or transient transfection with naked plasmid DNA, H

219 hed T cells and MCs from CMV-seropositive or CMV-seronegative donors, and for antigen uptake.

220 l models of viral dynamics upon initial oral CMV infection and validated them using clinical shedding

221 tently detected self-limited, low-level oral CMV shedding events, which we termed transient CMV infec

222 sient infections comprised 76 to 88% of oral CMV shedding events.

223 e estimated the likelihood of transient oral CMV infections by comparing their observed frequency to

224 Other CMV proteins associate with nucleoli, and we demonstrate

225 Among secondary outcomes, CMV reactivation in plasma was significantly lower in th

226 cells presented with lower initial and peak CMV loads (P < 0.05).

227 +), TNFalpha(+), and CCL3(+) polyfunctional, CMV-specific CD8(+) T cells.

228 A positive CMV PCR in newborns' saliva should always be confirmed i

229 patient developed CMV-T cell responses post-CMV viremia.

230 T cells through superantigen and to present CMV antigen to TH1 cells, co-opting MC secretory granule

231 n (28%) of 67 D+R- KTRs showed pretransplant CMV-specific T cells.

232 wo (80%) of 203 R+ KTRs showed pretransplant CMV-specific T cells.

233 Developing a vaccine to prevent CMV infection would be extremely valuable but would be f

234 In the absence of pUL31, CMV fails to reorganize nucleolin and UBF and exhibits a

235 onse to CMV antigens measured by Quantiferon-CMV (P = .0008).

236 An indeterminate Quantiferon-CMV result had a positive predictive value of 83% and a

237 onths after transplant using the Quantiferon-CMV, an enzyme-linked immunosorbent spot assay (ELISpot)

238 Quantifying CMV-specific T-cell immunity after HSCT can identify par

239 nd 21 who were asymptomatic) by quantitative CMV and beta-globin DNA-specific PCR.

240 which 17 patients were randomized to receive CMV pp65-specific T cells with CMV-DC vaccination (CMV-A

241 Patients who received CMV-ATCT-DC vaccination experienced a significant increa

242 ection (n = 109), matched by donor/recipient CMV serostatus, year and organ transplanted, and clinica

243 T-cell responses to 19 frequently recognized CMV proteins in "young" and "older" healthy volunteers a

244 Recurrent CMV occurred in 30.5% patients at a median of 51 (0-160)

245 Recurrent CMV occurs in a significant percentage of patients after

246 ility in the overall prevention of recurrent CMV disease.

247 nts at increased risk of clinically relevant CMV-related outcomes.

248 Upcoming revised CMV guidelines should incorporate organ transplant-speci

249 only elicited by a fibroblast-adapted rhesus CMV vector with limited tissue tropism; a repaired vecto

250 CMV-DC vaccination (CMV-ATCT-DC) or saline (CMV-ATCT-saline).

251 However, 75% showed CMV-T cell (+) by 2 months and 95% did so by 3 months po

252 We studied CMV acquisition in infants and found that infections are

253 licons of variable length were used to study CMV DNA fragmentation in 20 SOTR plasma samples, viral s

254 iding an unparalleled opportunity to subvert CMV antigens as tumor-specific immunotherapy targets.

255 etreatment with IFN-alpha failed to suppress CMV protein expression in patient fibroblasts, whereas e

256 who had suffered posttransplant symptomatic CMV infection in the cross-sectional study.

257 We conclude that CMV infection is associated with asthma and may contribu

258 This study establishes that CMV protein pUL31 is necessary and sufficient to regulat

259 TCR repertoire analysis revealed that CMV tet(low) and tet(high) CTLs use different TCRs.

260 The CMV colitis patients' demographic data, clinical informa

261 The CMV DNA was detected using commercial artus assay in 10.

262 The CMV-positive HEU infants had higher CRP than the CMV-neg

263 Our recent studies defining the CMV-induced nuclear proteome identified several viral pr

264 Higher steroid usage was noted in the CMV positive group compared to age and gender matched CM

265 y by their precursors without increasing the CMV reactivation risk after allogeneic SCT.

266 positive HEU infants had higher CRP than the CMV-negative HEU infants; this association disappeared a

267 Therefore, the CMV Drug Development Forum consisting of scientists, cli

268 CMV-specific T cells directed to CMV-IE1 and CMV-pp65 were measured by interferon-gamma E

269 osttransplantation, particularly directed to CMV-IE1, offers superior risk stratification compared wi

270 onth lag in recovery of specific immunity to CMV after initiating cART and suggest that "immune recov

271 healthy adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccina

272 were studied and classified with respect to CMV serostatus and presence of CMV-specific T cells.

273 interferon-gamma (IFN-gamma) in response to CMV antigens measured by Quantiferon-CMV (P = .0008).

274 and tet(high) CTLs were equally sensitive to CMV peptides in IFN-gamma release and cytotoxicity assay

275 antibody levels among those seropositive to CMV were also associated with shorter LTL at follow-up.

276 V shedding events, which we termed transient CMV infections, in a prospective birth cohort of 30 high

277 oxicity were present in aleumtuzumab-treated CMV sero (+) patients.

278 KTRs with decreasing/undetectable CMV-IE1-specific T cells pretransplantation and posttran

279 significantly higher prevalence of in utero CMV infection in ALL cases (n = 268) than healthy contro

280 65-specific T cells with CMV-DC vaccination (CMV-ATCT-DC) or saline (CMV-ATCT-saline).

281 Low levels of virion CMV DNA were found in 10 of 103 (9.7%) samples with high

282 osaic virus (AMV) and cucumber mosaic virus (CMV).

283 rrence of graft-versus-host disease, whereas CMV and BK virus reactivation did not predict clinical o

284 Greater knowledge of why CMV infection usually fails may provide insight into how

285 ed to receive CMV pp65-specific T cells with CMV-DC vaccination (CMV-ATCT-DC) or saline (CMV-ATCT-sal

286 developed CMV disease (n = 8) compared with CMV reactivation (n = 26) or spontaneous viral control (

287 s superior risk stratification compared with CMV serostatus alone.

288 hese numbers were positively correlated with CMV viral load in the dried blood spots.

289 were observed for CMV replication, KTRs with CMV-specific T cells presented with lower initial and pe

290 biquitin C promoter, and pEYFP-Mitotrap with CMV promoter).

291 patients without CMV colitis, patients with CMV colitis were more often older (p < 0.005).

292 Patients with CMV pneumonia had higher median viral loads (3.9 log10 I

293 < .001 for all comparisons to patients with CMV pneumonia).

294 eport a cluster of 5 pediatric patients with CMV retinitis diagnosed in a 12-month period and compare

295 eus superantigen and, when preincubated with CMV antigens, induce a recall CD4(+) TH1 proliferation r

296 L fluid samples from 132 HCT recipients with CMV pneumonia and 139 controls (100 patients with non-CM

297 Women with CMV viruria had significantly higher rates of HIV perina

298 Compared to CD patients without CMV colitis, patients with CMV colitis were more often o

299 reactivation compared with patients without CMV reactivation had a reduced proportion of polyfunctio

300 Among patients without CMV retinitis, 1 of 75 patients with immune recovery dev